论文部分内容阅读
[目的]观察哌拉西林钠舒巴坦钠联合甘露聚糖肽治疗盆腔炎症性疾病的疗效及安全性。[方法]将临床确诊的80例盆腔炎症性疾病患者随机分为两组，每组各40例。对照组：采用哌拉西林舒巴坦钠（2∶1）3．0 g加入0．9％氯化钠注射液500 m L静脉滴注，静脉滴注，1次/日，3～14 d为一疗程。试验组在上述治疗基础上加用甘露聚糖肽5 mg ，静脉滴注，1次/日，3～14 d为一疗程；比较两组治疗后疗效。[结果]治疗结束后，试验组治愈率和总有效率分别为87．5％（35/40）和97．5％（39/40），显著优于对照组（75％，87．5％）且两组相比较差异有显著性（均 P ＜0．05）。治疗过程中两组不良反应发生率分别为7．5％（3/40）和15％（6/40），试验组显著低于对照组，且两组相比较差异有显著性（ P ＜0．05）。[结论]哌拉西林舒巴坦钠联合甘露聚糖肽治疗盆腔炎症性疾病，其疗效显著优于单独使用哌拉西林舒巴坦钠，并且不良反应更少。“,”[Objective]To observe the efficacy and safety of piperacillin sodium and sulbactam sodium com-bined with mannatide for the treatment of pelvic inflammatory disease .[Methods]Totally 80 patients with pel-vic inflammatory disease were randomly divided into two groups with 40 patients in each group .The control group was given piperacillin sodium and sulbactam sodium (2∶1) 3 .0g with 0 .9% sodium chloride injection 500ml by intravenous infusion once a day for 3~14 days of a course .The experimental group was additionally given mannatide 5mg by intravenous infusion once a day for 3~14 day of a course bases on the above treat-ment .The efficacy was compared between two groups .[Results]After treatment ,the curative rate and total effective rate in experimental group were 87 .5% (35/40) and 97 .5% (39/40) respectively ,which were markedly better than those in control group(75% and 87 .5% ,respectively) ,and there was significant differ-ence between two groups(all P< 0 .05) .During the treatment ,the incidence of adverse reaction in two groups was 7 .5% (3/40) and 15% (6/40) respectively ,and that in experimental group was markedly lower than that in control group ,and there was significant difference( P<0 .05) .[Conclusion]The efficacy of piperacillin so-dium and sulbactam sodium combined with mannatide for the treatment of pelvic inflammatory disease is signif-icantly better than piperacillin sodium and sulbactam sodium alone ,and it has fewer adverse reactions .